Keppra (levetiracetam) and gabapentin are both anti-seizure medications, but they work through entirely different mechanisms in the brain, carry distinct side-effect profiles, and are prescribed for overlapping but not identical conditions. People often encounter these two drugs together because a neurologist is choosing between them, switching from one to the other, or occasionally prescribing both at once. Understanding how they compare helps make sense of why one might be chosen over the other in a given situation.
Two Completely Different Mechanisms
Despite both being classified as anti-seizure drugs, Keppra and gabapentin act on the brain in fundamentally different ways. Keppra binds to a protein called SV2A, which sits on the surface of synaptic vesicles, the tiny packets neurons use to release chemical signals. By latching onto SV2A, Keppra modulates how neurotransmitters are released, essentially dialing down excessive signaling without shutting it off entirely.1PubMed Central. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam This target is unique in the world of seizure drugs. When Keppra was discovered in 1992, it challenged the standard approach to finding anti-seizure medications, and the epilepsy research community was initially skeptical because it didn’t fit the mold of existing treatments.2PubMed. Levetiracetam: the first SV2A ligand for the treatment of epilepsy
Gabapentin, on the other hand, was originally designed to mimic GABA, the brain’s main calming neurotransmitter. Ironically, it doesn’t actually raise GABA levels in the brain.3PubMed. Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations Instead, its primary action comes from binding to a subunit of voltage-gated calcium channels called alpha-2-delta-1. Molecular and genetic studies strongly support this subunit as the sole molecular target responsible for gabapentin’s pain-relieving effects.4PubMed Central. Mechanisms of the gabapentinoids and α 2 δ ‐1 calcium channel subunit in neuropathic pain By binding to alpha-2-delta, gabapentin disrupts the trafficking of calcium channels over time, which reduces calcium influx into nerve terminals and ultimately dampens pain and seizure signaling.5PubMed. Time course and specificity of the pharmacological disruption of the trafficking of voltage-gated calcium channels by gabapentin
Interestingly, both drugs share a downstream effect: they reduce glutamate release, the brain’s main excitatory neurotransmitter. Keppra does this by modulating presynaptic calcium channels through SV2A.6PubMed Central. Levetiracetam inhibits glutamate transmission through presynaptic P/Q-type calcium channels on the granule cells of the dentate gyrus Gabapentin does it more indirectly through its effects on calcium channel trafficking. So while they arrive at a loosely similar endpoint, they take very different roads to get there, which matters for side effects, drug interactions, and the types of conditions they treat best.
Seizure Control and How They Compare
Both drugs are used to treat focal (partial) seizures, but their standing in epilepsy treatment is not equal. Keppra has become one of the most widely prescribed anti-seizure drugs worldwide and is used as a first-line treatment for several seizure types, including focal-onset seizures and certain generalized epilepsies. Gabapentin, while effective for focal seizures, is generally considered a second-tier option for epilepsy control.
A network meta-analysis comparing anti-seizure drugs for treatment-resistant focal epilepsy found that when both short-term effectiveness and tolerability were weighed together, levetiracetam and gabapentin both ranked favorably compared to some alternatives. The analysis prioritized sodium valproate, levetiracetam, and gabapentin among others when side effects were factored in alongside seizure reduction.7PubMed Central. Comparative efficacy and tolerability of anti-epileptic drugs for refractory focal epilepsy: systematic review and network meta-analysis reveals the need for long term comparator trials In animal models of drug-resistant epilepsy, both gabapentin and levetiracetam significantly raised seizure thresholds in rats that had failed to respond to phenytoin, one of the older standard treatments.8Epilepsy Research. Anticonvulsant efficacy of gabapentin and levetiracetam in phenytoin-resistant kindled rats
In practice, the distinction often comes down to potency and dosing convenience. Keppra can be dosed twice daily with predictable absorption at any dose, while gabapentin has a peculiar pharmacokinetic quirk discussed below that makes high-dose seizure control trickier. For these reasons, neurologists tend to reach for Keppra first when epilepsy is the primary concern, reserving gabapentin for situations where Keppra’s side effects are intolerable or when the patient also has significant nerve pain.
Beyond Seizures: Where Their Uses Diverge
Gabapentin has carved out a much larger role in pain management than Keppra has. It is one of the go-to drugs for neuropathic pain, the burning, shooting, or tingling pain that comes from nerve damage. Conditions like diabetic neuropathy, postherpetic neuralgia (the pain left behind after shingles), and certain types of chronic pain are common reasons for a gabapentin prescription. Its binding to the alpha-2-delta-1 calcium channel subunit is what drives this pain relief.9PubMed Central. Mechanisms of the gabapentinoids and α 2 δ ‐1 calcium channel subunit in neuropathic pain
Keppra is less commonly prescribed for pain, though some research has explored it. In a diabetic neuropathy mouse model, gabapentin at all tested doses improved mechanical pain thresholds, while levetiracetam achieved the same result only at its highest dose. Both drugs provided some protection for the sciatic nerve and spinal cord in the study.10PubMed. Effect of levetiracetam versus gabapentin on peripheral neuropathy and sciatic degeneration in streptozotocin-diabetic mice: Influence on spinal microglia and astrocytes This lines up with clinical experience: gabapentin is a proven pain drug, while Keppra’s pain-relieving potential is more limited and less established.
Gabapentin has also attracted research interest for alcohol use disorder. Single-site studies have found evidence that it can help reduce drinking, with particular benefits for alcohol-related insomnia and negative mood compared to other available treatments.11PubMed Central. Gabapentin for the treatment of alcohol use disorder Keppra does not have a comparable evidence base in this area. These off-label uses mean gabapentin prescriptions often go to people who have never had a seizure in their lives.
Can You Take Them Together?
Since Keppra and gabapentin work through different mechanisms, the idea of combining them for hard-to-control seizures is logical. In practice, some clinicians do prescribe both, particularly for patients whose seizures are not fully controlled by a single drug. The fact that neither drug significantly interferes with liver metabolism makes pharmacokinetic clashes between them unlikely. Both are primarily cleared through the kidneys, and both have very few drug interactions compared to older seizure medications.12SpringerLink / PubMed Central. Drug interactions with the newer antiepileptic drugs (AEDs)–part 1: pharmacokinetic and pharmacodynamic interactions between AEDs
That said, combining them does not guarantee a synergistic benefit. Research on post-traumatic seizures following penetrating brain injury tested the combination and found that the two drugs together did not even reach the expected level of additive benefit, let alone any synergistic effect.13PubMed. Combination therapy of levetiracetam and gabapentin against nonconvulsive seizures induced by penetrating traumatic brain injury This suggests that throwing both drugs at a seizure problem may not deliver twice the benefit. The combination is more often justified when each drug is targeting a different symptom: Keppra for seizure control and gabapentin for co-existing nerve pain, for example, rather than doubling up specifically for seizure suppression.
Different Side-Effect Personalities
Both drugs are generally considered well-tolerated compared to older anti-seizure medications, but their side-effect profiles have distinct characters. Keppra’s most notorious issue is behavioral and psychiatric. While most people tolerate it fine, a minority develop mood changes shortly after starting the drug or changing the dose, including anxiety, agitation, and depression.14PubMed Central. Levetiracetam-induced aggression and acute behavioral changes: A case report and literature review In a study of over 1,400 epilepsy patients on levetiracetam, about 8% developed severe psychiatric symptoms, including hallucinations, delusions, aggressive behavior, and agitation. Some patients also experienced suicidal thoughts or self-harm behaviors.15PubMed. Levetiracetam induces severe psychiatric symptoms in people with epilepsy This is sometimes colloquially called “Keppra rage” in patient communities, and while the proportion of people affected is relatively small, it can be dramatic enough to force a drug switch.
Gabapentin’s side effects lean more toward sedation and physical symptoms. Drowsiness, dizziness, and fatigue are the most common complaints. In some cases, even low doses can cause significant physical impairment. One case report documented a patient who developed weakness in the lower limbs and trouble walking after starting just 200 mg of gabapentin, the lowest typical dose.16PubMed Central. A case of gait disturbance caused by low-dose gabapentin This kind of motor side effect is more relevant for older adults, who are also more susceptible to falls from the dizziness gabapentin can cause.
In short, if your neurologist is worried about mood and behavioral changes, gabapentin may look like the safer choice. If sedation and unsteadiness are the bigger concern, Keppra’s profile may be more appealing. Neither drug is free of side effects, but the types of problems they tend to cause are different enough that one can sometimes step in when the other is causing trouble.
A Quirk in Gabapentin’s Absorption
One of gabapentin’s most clinically important features is how the body absorbs it. Unlike most drugs, gabapentin does not follow a simple “more drug in, more drug absorbed” pattern. Instead, its absorption is saturable, meaning the gut can only take up so much at a time. As the dose increases, the percentage that actually reaches the bloodstream decreases.17PubMed Central. Pharmacokinetics and Saturable Absorption of Gabapentin in Nursing Home Elderly Patients At low doses, a high fraction gets absorbed. At very high doses, a significant portion passes through the gut unused.
This has practical consequences. It means that tripling the dose does not triple the drug level in your blood, which can frustrate attempts to push gabapentin to higher doses for seizure control or severe pain. It also means splitting the total daily dose into three or even four smaller doses throughout the day can actually improve overall absorption compared to taking it in fewer, larger doses. Keppra does not have this problem; its absorption is linear and predictable regardless of dose. This difference is one reason Keppra is generally preferred when reliable seizure control is the top priority and dosing flexibility matters.
Who Stays on Which Drug
Whether people stick with a medication over time says a lot about real-world tolerability. A large study from German neurology practices found meaningful differences between these two drugs. Patients on gabapentin were significantly more likely to stop taking it compared to patients on levetiracetam. The data showed gabapentin carried about a 46% higher risk of non-persistence, while levetiracetam was associated with about a 31% lower risk of discontinuation compared to the study’s baseline.18PubMed. Persistence with antiepileptic drugs in epilepsy patients treated in neurological practices in Germany
This gap likely reflects gabapentin’s sedation burden, its three-times-daily dosing requirement (compared to Keppra’s twice daily), and its weaker seizure control at achievable blood levels due to the absorption ceiling. Keppra’s main reason for discontinuation tends to be the psychiatric side effects, which, while troubling, affect a smaller fraction of users than gabapentin’s more universal sedation does. For patients who tolerate Keppra without mood disturbances, sticking with it over the long term appears to be easier.
Drug Interactions and Why These Two Are “Clean”
Older anti-seizure drugs like phenytoin, carbamazepine, and phenobarbital are notorious for interacting with other medications because they are metabolized by liver enzymes and can dramatically speed up or slow down the processing of other drugs. Both Keppra and gabapentin largely avoid this problem. They are primarily cleared by the kidneys, and neither significantly induces or inhibits the liver enzymes responsible for processing most other medications. Gabapentin in particular has among the fewest pharmacokinetic interactions of any seizure drug, with five or fewer documented interactions.19SpringerLink / PubMed Central. Drug interactions with the newer antiepileptic drugs (AEDs)–part 1: pharmacokinetic and pharmacodynamic interactions between AEDs
This “clean” interaction profile is especially useful for people taking multiple medications, which is common in older adults and in patients with conditions like cancer or HIV where the drug regimen is already complex. It also means that when both drugs are prescribed together, they do not compete for the same metabolic pathways or alter each other’s blood levels in a clinically meaningful way. The main interaction concern with both drugs is additive sedation when combined with each other or with other central nervous system depressants like opioids or benzodiazepines.
Older Adults and Kidney Function
Both drugs are reviewed as options for older adults with epilepsy, alongside other newer agents.20PubMed. Antiseizure Medications in Older Adults with Epilepsy: Considerations in Pharmacology, Safety, Tolerability, and Effectiveness of Newer Agents Because both are cleared through the kidneys, declining kidney function, which is common with aging, directly affects how quickly the body eliminates them. Doses typically need to be reduced in proportion to kidney function, and failing to adjust can lead to drug accumulation and worsening side effects like excessive sedation, confusion, or in Keppra’s case, behavioral changes.
The absorption quirk in gabapentin becomes even more relevant in older adults. The saturable absorption pattern has been specifically documented in nursing home patients, where the already limited bioavailability at higher doses compounds with slower kidney clearance to make dose optimization tricky.21PubMed Central. Pharmacokinetics and Saturable Absorption of Gabapentin in Nursing Home Elderly Patients For frail older adults in particular, gabapentin’s sedation and fall risk can be more dangerous than Keppra’s psychiatric effects, since a hip fracture from a fall can be life-threatening at that age. Conversely, for an older adult who already struggles with mood or who has cognitive impairment, gabapentin’s calming properties might actually be preferable if the sedation is manageable.
How Keppra’s Discovery Changed the Field
The story of how levetiracetam reached the clinic is unusual. Most anti-seizure drugs were found by testing compounds in standard laboratory models, particularly the maximal electroshock test, which favors drugs that block sodium channels. Levetiracetam was inactive in that test, which initially made researchers doubt it could work as a seizure drug at all. It was only identified because it was also screened in an audiogenic (sound-triggered) seizure model in mice, a less commonly used approach.22PubMed Central. Brivaracetam: a rational drug discovery success story Its binding target, SV2A, was not identified until several years later, and it remained uncertain for some time exactly how the drug worked.23PubMed. Structures of synaptic vesicle protein 2A and 2B bound to anticonvulsants
Gabapentin’s origin story has its own irony. It was rationally designed to be a GABA analogue that could cross the blood-brain barrier, something GABA itself cannot do easily. The drug was successful, but not for the reason its creators intended. It turned out not to act on GABA receptors at all, and instead found its therapeutic niche through the alpha-2-delta calcium channel subunit that nobody was initially looking at.24The Journal of Pharmacology and Experimental Therapeutics. Minireview Mechanism of Analgesia by Gabapentinoid Drugs: Involvement of Modulation of Synaptogenesis and Trafficking of Glutamate-Gated Ion Channels Both drugs are reminders that in pharmacology, the compound you design does not always do what you expect, and sometimes the accidental mechanism turns out to be more useful than the intended one.